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Summary 
 
Liver regeneration depends on the proliferation of mature hepatocytes. In the 1980s, the 
method for the cultivation of mature hepatocytes provided an opportunity for the discovery of 
hepatocyte growth factor (HGF) as a protein that is structurally and functionally different 
from other growth factors. In 1991, the scatter factor, tumor cytotoxic factor, and 3-D 
epithelial morphogen were identified as HGF, and Met tyrosine kinase was identified as the 
receptor for HGF. Thus, the connection of apparently unrelated research projects rapidly 
enriched the research on HGF in different fields. The HGF-Met pathway plays important roles 
in the embryonic development of the liver and the placenta, in the migration of myogenic 
precursor cells, and in epithelial morphogenesis. The use of tissue-specific knockout mice 
demonstrated that in mature tissues the HGF-Met pathway plays a critical role in tissue 
protection and regeneration, and in providing less susceptibility to chronic inflammation and 
fibrosis. In various injury and disease models, HGF promotes cell survival, regeneration of 
tissues, and suppresses and improves chronic inflammation and fibrosis. Drug development 
using HGF has been challenging, but extensive preclinical studies to address its therapeutic 
effects have provided significant results sufficient for the development of HGF as a biological 
drug in the regeneration-based therapy of diseases. Clinical trials using recombinant human 
HGF protein, or HGF genes, are in progress for the treatment of diseases.  
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Introduction: Before 1991 
 A mysterious phenomenon, perhaps even now, is the vital ability of the liver to 
regenerate. After experimental partial hepatectomy in mice and rats, for which two-thirds of 
the liver is removed, the residual liver tissue enlarges to make up for the mass of the removed 
tissue. The entire process can be completed within only one week. An in vitro cell culture 
technique for rat hepatocytes provided a scientific background to help explain liver 
regeneration. In 1984, hepatocyte growth factor (HGF) was discovered as a mitogenic protein 
for rat hepatocytes,1, 2 and was thereafter purified from rat platelets,3 human plasma,4 and 
rabbit plasma.5  
 In 1989, cDNA for human HGF was cloned and the primary structure of HGF was 
clarified, by which HGF was identified as a novel growth factor with unique structural 
characteristics.6, 7 Biologically active HGF, a protein composed of 697 or 692 amino acids, is 
a heterodimeric molecule composed of an -chain and a -chain (Fig. 1A). The -chain 
contains four kringle domains, while the -chain contains a serine protease-like structure. A 
striking fact is that HGF has a structural similarity to plasminogen, which is a heterodimeric 
serine protease containing five kringle domains. 
 In 1991, we contributed to this journal by providing our review article entitled 
“Hepatocyte growth factor: molecular structure and implications for a central role in liver 
regeneration.”8 In that review we described the structural characteristics of HGF, changes in 
its expression following liver injury, and newly identified target cell types and the biological 
action of HGF. Before 1991, studies on HGF were done only by a small number of research 
groups, and total publications on HGF numbered less than 20 (Table 1). Research on HGF has 
widely spread and currently over 300 publications appear each year worldwide. After 20 years, 
recombinant human HGF is currently in clinical trials for treatment of diseases. In this review, 
we attempt to track 20 years of HGF research and development.  
 
In 1991 
 In 1991, there was unexpected landmark progress in research on HGF (Table 1). The 
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scatter factor, originally identified as a fibroblast-derived cell motility factor for epithelial 
cells,9 was shown to be an identical molecule to HGF. Similarly, tumor cytotoxic factor, a 
fibroblast-derived factor that induces cell death for several cancer cell types, was shown to be 
an identical molecule to HGF.10 These bioactive molecules were identified and characterized 
using biological assays from different groups.  
 The induction of branching tubulogenesis in renal epithelial cells by HGF had a 
particular impact on cell and developmental biologists, because among growth factors and 
bioactive molecules HGF was the first to induce 3-dimensional (3-D) morphogenesis.11 It had 
long been recognized that morphogenesis of epithelial tissues required an interaction with the 
adjacent mesenchyme (during embryonic development) or with the adjacent stroma (during 
postnatal life), which is known as the epithelial-mesenchymal interaction. However, the 
molecule that mediated the inducing effect of mesenchyme or stroma on epithelial 
morphogenesis was yet to be identified. HGF was the hitherto unidentified 
mesenchymal-derived molecule in epithelial-mesenchymal interaction that was responsible 
for epithelial morphogenesis.  
 The receptor for HGF was identified as a product of the c-met proto-oncogene in 
1991.12, 13 The Met receptor is composed of structural domains that include the extracellular 
Sema, PSI and IPT domains, the transmembrane domain, and the intracellular juxtamembrane 
and tyrosine kinase domains (Fig. 1B). The binding of HGF to the Met receptor induces 
activation of Met tyrosine kinase and the autophosphorylation of tyrosine residues in Met. 
 Scientific research sometimes unexpectedly turns in unanticipated directions. The 
connection and integration of research and molecules previously thought to be unrelated, i.e., 
HGF, scatter factor, tumor cytotoxic factor, 3-D epithelial morphogen, and Met, rapidly 
enriched the research on HGF in different fields.  
 
3-D Morphogenesis and organogenesis in development 
 The essential roles of the HGF-Met pathway in mammalian development have been 
defined by the targeted disruption of the HGF or Met genes.14-16 In these studies, the 
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embryonic liver is reduced in size and shows extensive apoptotic cell death. The knockout is 
embryonically lethal due to impaired organogenesis of the placenta and liver. In the placenta, 
the number of labyrinthine trophoblasts is markedly reduced. It is noteworthy that HGF-Met 
participates in a long-distance migration of cells in development, which indicates a particular 
role for HGF in cell movement. In the mouse embryo, HGF is strongly expressed in the limb 
bud mesenchyme and septum transversum (which develops into the diaphragm), and the 
migration of Met-positive myogenic precursor cells from dermo-myotome in the somite to 
limb buds and diaphragm is impaired in Met-/- embryos. Consequently, skeletal muscles of the 
limb and diaphragm are not formed in mutant mice.16 Thus, HGF provides spatially defined 
chemoattractant-like motogenic signals for the migration of myogenic precursor cells.17 
 Using a gene knock-out/knock-in approach and sterotaxic injections of HGF or 
neutralizing antibody into the striatum in mice reveals the critical role of HGF in the 
development of the nervous systems.18 HGF functions as an axonal chemoattractant for spinal 
motor neurons and for the projection of motor neurons to limb muscle.19 In addition, HGF 
plays important roles in the development of sensory, sympathetic, parasympathetic, and 
cortical neurons. HGF regulates the proliferation of oligodendrocyte progenitor cells and their 
differentiation into oligodendrocytes.20 Thus, HGF is implicated in neuronal as well as glial 
development in an orchestrated manner. 
 HGF regulates epithelial development and morphogenesis in different organs.17, 21 In 
organ culture experiments, antibodies against HGF inhibit branching tubulogenesis of 
developing epithelia in the kidney and mammary glands. In tooth germ culture, antisense 
oligonucleotide to HGF induces impaired morphogenesis of tooth epithelium, which 
subsequently differentiates into ameloblasts. In organ cultures of the developing lung, 
branching morphogenesis of developing lung epithelia is inhibited by neutralization of HGF 
or use of an antisense strategy. During the development of various tissues, Met is expressed in 
the epithelia, while the HGF in mesenchymal cells is in close vicinity in various organs. These 
expression patterns indicate that HGF is a mesenchymal-derived factor that predominantly 
acts on neighboring developing epithelia.17 Interactions between epithelium and mesenchyme, 
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i.e., epithelial-mesenchymal interactions mediate crucial aspects of development, affecting 
tissue induction and epithelial morphogenesis. Thus, HGF plays important roles as a 
mesenchymal-derived factor that regulates epithelial growth and morphogenesis. 
 
Physiological roles 
 Far beyond the initial prediction that HGF plays a particular role in the regulation of 
liver growth and regeneration, the diverse biological and physiological roles of the HGF-Met 
pathway have been studied in diverse cell types (Table 2). In addition to the mitogenic, 
motogenic (enhancement of cell motility), and 3-D morphogenic activities of HGF — those 
known prior to 1991 — an increasing number of studies done in the early 1990s on apoptosis 
were connected to the remarkable action of HGF in the suppression of apoptotic cell death 
(Fig. 2). Activation of the Fas receptor by agonistic antibody in mice induces fulminant 
hepatitis associated with massive apoptosis of hepatocytes, whereas HGF potently suppresses 
apoptotic death of hepatocytes, thereby preventing the onset of fulminant hepatitis in mice.22 
The suppression of cell death by HGF participates in the biological, physiological, and 
therapeutic actions of HGF. The impaired development of the HGF or Met gene in the 
embryonic livers of systemic knockout mice was explained by submassive apoptosis in the 
hepatoblasts. The cytoprotective action of HGF explains how it suppresses the onset of tissue 
damage, including acute liver injury. However, it is noteworthy that HGF bidirectionally 
regulates cell survival in a cell type-dependent manner. In a model of liver cirrhosis in rats, 
HGF suppressed apoptosis of hepatocytes but facilitated apoptosis of -smooth muscle and 
actin-positive myofibroblasts, the cells responsible for tissue fibrosis.23  
 Induction of proteases involved in breakdown of the extracellular matrix scaffold was 
also revealed as a particular action of HGF. HGF induces or up-regulates expression of 
urokinase-type plasminogen activator and matrix metalloproteinases (MMPs) such as 
membrane-type MMP and MMP-9. Induction of these proteases also participates in the 
biological, physiological, and therapeutic actions of HGF (Fig. 2). For 3-D epithelial 
branching tubulogenesis by HGF, activation of urokinase-type plasminogen activator and 
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membrane type 1-MMP play a crucial role. Enhancement in the expression of MMPs is a 
mechanism by which the fibrotic change in tissues is suppressed and/or the resolution of 
fibrosis is facilitated by HGF. Instead, the induction of MMPs, such as membrane types 
1-MMP and MMP-9, participates in the 3-D spreading and invasion of cancer cells.  
 In accord with the initial implication of HGF as a humoral hepatotrophic factor that 
enhances liver regeneration, expression of HGF is increased in response to liver injuries. 
Conversely, neutralization of endogenous HGF enahances liver damage, for example by 
increasing apoptosis/necrosis of hepatocytes and/or suppression of liver regeneration. The 
hepatotrophic role of HGF was definitively demonstrated using a conditional knockout of the 
Met gene in mice.24-26 Mice lacking the Met gene in hepatocytes were hypersensitive even to 
mild liver injury caused by administration of a low-dose of agonistic anti-Fas antibody, 
indicating that anti-apoptotic activity of HGF plays a role in protection of the liver. Liver- or 
hepatocyte-specific Met-/- mice showed delayed liver regeneration associated with persistent 
inflammatory reaction, and were susceptible to fibrotic change in the liver. Likewise, after 
bile duct ligation that causes chronic cholestatic liver injury, hepatocyte-specific Met-/- mice 
showed increases in hepatocyte apoptosis, inflammation, and profibrogenic responses, and 
were more susceptible to chronic inflammation and fibrotic change compared with control 
mice.26 These effects in liver- or hepatocyte-specific Met-/- mice clearly indicate that the 
physiological roles of the HGF-Met pathway in protection, regeneration, anti-inflammation, 
and anti-fibrosis of the liver cannot be substituted by other growth factors, cytokines, and 
bioactive molecules. Thus, the hepatotrophic and hepatoprotective roles of HGF have been 
well established during the past 20 years. 
 Similar to the story of HGF-Met in the liver, the involvement of the HGF-Met pathway 
in tissue protection and/or regeneration has been demonstrated in different tissues, though the 
dependency on the HGF-Met pathway is different depending on tissue types. The HGF-Met 
pathway supports the protection and regeneration of kidney, lung, nervous system, 
cardiovascular, cutaneous, and gastrointestinal tissues. Collectively, the HGF-Met pathway 
plays definitive roles not only by promoting survival, proliferation, migration, and 3-D 
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morphogenesis but also in preventing inflammation and fibrotic change in tissues. Studies 
using tissue-specific Met knockout mice provided clear evidence for the roles of the 
HGF-Met pathway in protection, regeneration, and anti-fibrosis/inflammation in different cell 
and tissue types.  
 Mice with conditional knockout of Met in the collecting duct of the kidney were more 
susceptible to interstitial fibrosis and tubular necrosis after unilateral ureteral obstruction, 
while they had reduced capacity in tubular cell regeneration after release of the obstruction, 
leading to diminished functional recovery.27 In podocyte Met conditional knockout mice, no 
pathology was seen, whereas the mice developed more severe podocyte apoptosis and 
albuminurea in comparison with control mice.28 Disruption of the Met gene in epidermal 
keratinocytes demonstrated in an indispensable role for the HGF-Met pathway in skin wound 
healing.29 Surprisingly, Met-deficient epidermal keratinocytes	were unable to contribute to the 
re-epithelialization of skin wounds, though other growth factors and bioactive molecules were 
functional.  
 Conditional knockout mice with selective disruption of Met in pancreatic -cells 
displayed significantly reduced plasma insulin after a glucose challenge. In vitro 
glucose-stimulated insulin secretion in the isletsfrom -cell-Met-/- mice was decreased by 
~50% compared with control islets. These changes in -cell function in conditional Met 
knockout mice were not accompanied by changes in total -cell mass, islet morphology, and 
-cell proliferation.30 Another group using -cell-Met-/- mice displayed mild hyperglycemia 
and a complete loss of acute-phase insulin secretion in response to glucose.31 Therefore, 
HGF-Met signaling in the -cell is not essential for -cell growth, but it is essential for 
normal glucose-dependent insulin secretion and glucose homeostasis. 
 Because aberrant activation of growth factor receptors is generally associated with 
tumor development, a lack of growth factor receptor-mediated signal could be associated with 
less tumor development. However, a role of the HGF-Met pathway in hepatocarcinogenesis 
has been debated. Unexpectedly, when compared with control mice, liver-specific Met-/- mice 
treated with N-nitrosodiethylamine developed significantly more tumors that were larger and 
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had a shorter latency. N-nitrosodiethylamine induced oxidative stress, whereas administration 
of antioxidant blocked the hepatocarcinogenesis in liver-specific Met-/- mice.32 Thus 
HGF-Met signaling is essential for maintaining normal redox homeostasis in the liver and has 
tumor suppressor effect(s) in this model. In a model of hepatocarcinogenesis induced by 
N-nitrosodiethylamine and phenobarbital, liver-specific Met-/- mice showed a higher 
prevalence of macroscopically visible liver tumors, while there was only minor differences in 
the number of preneoplastic and neoplastic lesions in response to phenobarbital-induced 
promotion. These results indicate that a defect in Met-mediated signaling increases 
chemically induced tumor initiation in liver but does not significantly affect 
phenobarbital-mediated tumor promotion.33 
 
Processing and physiological relevance 
 HGF is biosynthesized as a prepro-form of 728 amino acids, including a signal 
sequence and both - and -chains. After cleavage of a signal peptide of the first 31 amino 
acids, a single-chain HGF is further cleaved between Arg494 and Val495, and this processing 
is coupled to the conversion of biologically inactive pro-HGF to active HGF. It has been 
proposed that several proteases in the serum or cell membranes are involved in the activation 
of single-chain HGF, including HGF activator (HGF-A), urokinase-type plasminogen 
activator, plasma kallikrein, coagulation factors XII and XI, matriptase, and hepsin. Among 
them, HGF-A, matriptase, and hepsin are the most efficient in processing proHGF. HGF-A 
was purified and cloned as a serum-derived protease that activates HGF.34, 35 HGF-A is a 
member of the kringle-containing serine protease superfamily. HGF-A is biosynthesized 
primarily by hepatocytes and circulates in the plasma as an inactive single-chain proHGF-A. 
Because significant activation of proHGF occurs in injured tissues and thrombin activates 
proHGF-A, the conversion of prothrombin to thrombin, which occurs during activation of the 
coagulation cascade, is involved in the activation of HGF in response to tissue injury. In 
addition, kallikrein 1-related peptidases participate in the activation of proHGF-A, and this 
activation is believed to occur in the pericellular microenvironment.  
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 The activity of HGF-A is regulated not only by its processing from proHGF-A, but also 
by a specific inhibitor, HGF-A inhibitor-1 (HAI-1).36 HAI-1 is a membrane-bound serine 
protease inhibitor that is mainly expressed on the basolateral surfaces of epithelial cells. 
HGF-A can be localized to the pericellular microenvironment via its affinity to heparansulfate 
and/or binding to HAI-1. The activity of HGF-A is suppressed by its binding to the cell 
surface HAI-1. On the other hand, the HGF-A and HAI-1 complexes on the cell surface can 
potentially be released by metalloprotease-mediated shedding of the HAI-1 ectodomain, and 
this process is enhanced by inflammatory cytokines such as interleukin-1. Perhaps, HAI-1 
plays a role not only as an inhibitor but also as a cell-associated reservoir of HGF-A. The 
regulatory mechanism for the activation of proHGF by HGF-A and HAI-1 can be 
considerable as the physiological link between inflammation and tissue regeneration. In this 
context, it is notable that inflammatory mediators such as interleukin-1, prostaglandin E2, 
and prostaglandin I2 are potent inducers for the expression of HGF, again implicating a 
physiological link from inflammation to tissue regeneration. 
 The physiological significance of HGF-A has been studied by loss-of-function 
approaches.35, 36 The inhibition of HGF-A by neutralizing antibody resulted in impairment in 
activation of proHGF.35 The knockout approach using mice lacking HGF-A indicated that the 
sera from HGF-A-/- mice were unable to activate proHGF, indicating that HGF-A is the major 
protease responsible for the activation of HGF in serum.37 Although HGF-A-/- mice showed 
normal development, the attenuation of initial regeneration after mucosal injury was 
associated with impaired restitution of epithelia. Pathophysiological study has indicated that 
fibroblasts from patients with idiopathic pulmonary fibrosis have a lower capacity to activate 
pro-HGF compared with control fibroblasts.38 Therefore, the process for activation of HGF 
also plays an important role in the regulation of tissue regeneration and susceptibility to 
pathological conditions.  
 
Therapeutic approaches and clinical development 
 The highlights in research on HGF during the past 20 years have resulted in extensive 
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therapeutic approaches using different disease models for different tissues (Table 3). Even in 
different injury and tissue types, the mechanisms responsible for the therapeutic effects of 
HGF are likely to overlap (Fig. 2). The protective actions of HGF are explained by prevention 
of cell death against various types of stresses and injury. Prevention of cell death by HGF 
seems to be associated with less subsequent inflammation, or an anti-inflammatory effect, 
whereas mechanisms by which HGF could regulate immunological responses have yet to be 
addressed. Recent studies have indicated that HGF regulates the function of immune cells 
such as dendritic cells and a subset of regulatory T cells.39-41 These biological actions of HGF 
on immune cells are likely to be the underlying mechanism, at least in part, by which HGF 
exerts therapeutic effects on diseases associated with allergy, inflammation, and fibrosis.  
 On the other hand, promotion of cell proliferation, migration, and 3-D morphogenesis 
by HGF explains the recovery and re-organization of tissues from injury, whereas the 
dynamic reconstruction of 3-D tissue structure substantially supports functional recovery. 
Chronic tissue injury is tightly associated with the onset of fibrotic change, and this is 
particularly relevant to the pathogenesisof liver cirrhosis and chronic kidney disease; there has 
been no effective therapeutic approach for the treatment of such chronic fibrotic diseases. It 
should be emphasized that, at least in animal models, HGF-treatment is highly effective for 
the treatment of chronic fibrosis in various disease models, including liver cirrhosis, chronic 
kidney disease, dilated cardiomyopathy, lung fibrosis, and vocal fold scarring.  
 The first clinical study using recombinant human HGF protein was done to investigate 
the physiological and therapeutic effects of HGF on chronic leg ulcers. HGF in gel form was 
locally applied to chronic leg ulcers in 11 patients.42 The first clinical study of HGF gene 
therapy by naked expression plasmid was done to investigate its safety for treatment of 
patients with arteriosclerosis obliterans or Buerger disease.43 Subsequently, a multicenter, 
randomized, double-blind, placebo-controlled clinical trial was performed for the treatment of 
patients with critical limb ischemia to evaluate the efficacy and safety of HGF gene therapy 
using naked plasmid.44 This HGF gene therapy was proven safe and effective for critical limb 
ischemia. Phase-II and Phase-III clinical trials of HGF gene therapy for the treatment of 
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peripheral arterial disease has been completed in both the USA and Japan. The phase-I clinical 
trial of the systemic administration of recombinant HGF protein and the Phase-I/II clinical 




 The C-terminal multifunctional docking site of Met plays a crucial role in the activation 
of Met-dependent intracellular signal transduction and biological activities.45 The 
phosphorylation of C-terminal tyrosine residues in the docking site recruit intracellular 
signaling molecules, including PI3K (phosphatidylinositol 3-kinase), Grb2 
(growth-factor-receptor-bound protein 2), Gab1 (Grb2)-associated binder 1), PLC 
(phospholipase C), and Shp2 (SH2-domain-containing protein tyrosine phosphatase 2). 
Among signaling molecules, a scaffolding adaptor protein, Gab1, is the most crucial substrate 
for the HGF-Met pathway.46 Direct interaction of Gab1 with tyrosine phosphorylated Met is 
mediated by the Met-binding site in Gab1, and it allows a direct and robust interaction 
between Met and Gab1. Knockout mice with the Gab1 gene exhibited phenotypes similar to 
those seen in HGF and Met knockout mice.46 
 In terms of Met-dependent signal transduction, the cytoplasmic juxtamembrane domain, 
which is composed of 47 highly conserved amino acids, acts as a negative regulator. Cbl, an 
E3 ubiquitin ligase, binds phosphorylated Y1003 of Met, and this Cbl binding results in Met 
ubiquitination, endocytosis, transport to the endosomal compartment, then degradation.47 
Cbl-mediated degradation of the activated Met provides a mechanism that attenuates or 
terminates Met-mediated signaling. Phosphorylation of Ser985 in the juxtamembrane domain 
regulates the activation status of Met upon HGF stimulation. Ser985 is phosphorylated by 
protein kinase-C and is dephosphorylated by protein phosphatase-2A. In cells in which 
Ser985 is phosphorylated by treatment with protein kinase-C, HGF-induced activation of Met 
is suppressed.48, 49 Therefore, activation of protein kinase-C, which occurs by different types 
of extracellular stimuli, regulates HGF-dependent Met activation. 
20 years of HGF 11/02/10  -13- 
 HGF binds to Met through two different mechanisms: the -chain binds with high 
affinity while the -chain binds with very low affinity. Among the -chain binding sites, NK1 
(the N-terminal and first kringle domains) in the -chain of HGF provides high-affinity 
binding to Met (Fig. 1A). The -chain alone exhibits high-affinity binding to Met, whereas 
the binding of the -chain does not activate Met.50 When Met is occupied by the -chain, the 
low-affinity binding of the -chain induces activation of Met and biological responses. Hence, 
the -chain is a high-affinity binding module to Met, while the -chain is an activation 
module for Met.  
 The structure of the complex of HGF -chain and Sema was revealed by 
crystallographic analysis (Fig. 3A).51 The Sema domain of Met forms a seven-bladed 
-propeller, which makes the shape of the Sema domain resemble a funnel. Generally, in 
-propellers each of the blades is formed by four antiparallel -strands. The HGF -chain 
binds to the bottom face of the propeller, and forms contacts with residues that protrude from 
blades 2 and 3. The HGF -chain binds to a series of protruding polar side chains from Met, 
which originate from three separate loops: residues 124-128, residues 190-192, and residues 
218-223 (Fig. 3A). Although the -chain of HGF binds to Met with much higher affinity than 
that of the HGF -chain, the crystal structure for the interaction between the HGF -chain and 
the extracellular region of Met has yet to be determined.  
 The Met tyrosine kinase domain follows the bilobal protein kinase architecture mainly 
with an N-terminal, -sheet-containing domain linked through a hinge segment mainly to the 
-helical C lobe (Fig. 3B).52, 53 The characteristic feature of Met is the presence of the 
C-terminal multifunctional docking site that contains tyrosine residues 
(1349YVHVNAT1356YVNV). In an unphosphorylated Met kinase domain, Met 1229 in the 
activation loop (A-loop, yellow in Fig. 3B) projects into the ATP-binding pocket, and the 
direction of the Glu 1127 residue involved in ATP-binding is changed, by which ATP is 
unable to form an appropriate structure for the kinase-substrate complex.53 This structure 
corresponds to the quiescent autoinhibited Met kinase without HGF stimulation. On the other 
hand, the autoinhibited Met kinase structure changes upon the phosphorylation of Tyr 1234 
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and Tyr 1235 in the activation loop, which allows a complex formation between the Met 
kinase and ATP.  
 The staurosporine analog K-252a inhibits Met tyrosine kinase through its binding in the 
ATP pocket.52 Because the structure of the Met kinase domain, complexed with the K-252a as 
shown in Fig. 3B, was obtained using the recombinant Met kinase domain where Tyr 1234 
and Tyr 1235 were replaced by Phe and Asp, respectively, Met kinase complexed with K-252a 
is expected to represent a structure of Met tyrosine kinase that is activated upon 
HGF-stimulation. 
 
HGF in tumor biology and therapeutics 
 The HGF-Met system drives the breakdown of the extracellular matrix and the 
concomitant cellular migration, mitogenesis, and morphogenesis, leading to the construction 
of tissue architecture. In cancer tissues, biological programs regulated by the HGF-Met 
pathway are adopted particularly for invasion and metastasis, which are the life-threatening 
events of cancer. Early studies indicating the identity of a fibroblast-derived scatter factor in 
HGF implicated a role for HGF in cancer spreading and invasion.54 The crucial role of 
stromal fibroblasts in invasion of cancer cells through the 3-D collagen was first demonstrated 
independently using human oral squamous cell carcinoma.55 The cancer cells invaded 
aggressively only when they were co-cultured with stromal fibroblasts in collagen gel. The 
fibroblast-derived factor responsible for the 3-D invasion was thereafter identified as HGF. 
The profound action of HGF on cancer invasion has been demonstrated in a variety of cancer 
cells, and it has been established that HGF is a mediator in the tumor-stromal interaction that 
affects the malignant behavior of cancer.56 
 In addition to the paracrine activation of Met through tumor-stromal interaction, Met 
activation in cancer often occurs through an autocrine mechanism, or through a mutation in 
the Met gene. Genetical analysis indicated that missense mutations in the c-met gene are the 
causative genetical disorder in inherited, and some sporadic papillary, renal carcinomas.57 
Mutations found in papillary renal carcinomas are located in the tyrosine kinase domain of the 
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c-Met receptor, and these Met receptor mutations are likely to be a gain-of-function 
mutation.58 In addition to papillary renal carcinoma, missense mutations in the Met have been 
found in lung cancer, hepatocellular carcinoma and gastric cancer; sites include the Sema, IPT, 
juxtamembrane, and tyrosine kinase domains.59  
 The HGF-Met pathway has become a hot target in anticancer drug development.60, 61 
Several distinct lines of approach to the inhibition of the HGF-Met pathway have been 
demonstrated, including small molecules that inhibit Met tyrosine kinase activity, ribozymes, 
small-interfering RNA (siRNA), neutralizing monoclonal antibodies, soluble Met receptors, 
and antagonists composed of selected domains in HGF (Fig. 4A). Among these approaches to 
the inhibition of the HGF-Met pathway, NK4 was the first-identified specific inhibitor for 
HGF-Met.62, 63 NK4 is composed of the N-terminal (N) and four kringle domains (K4) of 
HGF, and it is a competitive inhibitor of HGF-dependent Met activation (Fig. 4B). Discovery 
of NK4 as a competitive inhibitor for HGF-Met was soon followed by the experimental 
treatment of cancer in mice: NK4 inhibited the invasion and growth of gallbladder cancer.64 It 
is also noteworthy that NK4 is bifunctional — it is an angiogenesis inhibitor as well as an 
HGF-Met inhibitor.63, 65 The inhibition of tumor growth by NK4 treatment has been observed 
in a variety of tumors, and this inhibitory effect has been associated with a reduction in blood 
vessels in tumor tissues. NK4 treatment inhibited invasion and metastasis in different types of 
cancer models, including breast, colon, gastric, lung, ovarian, and pancreatic carcinomas, and 
malignant melanoma.63 
 If metastatic tumors could be suppressed to a non-metastatic state, there would be a 
considerable improvement in rate of cancer cures. Recent studies have indicated that cancer 
stem cells participate in drug-resistance and in the spreading of tumors, indicating that cancer 
stem cells are therapeutic targets for future advancements in anti-cancer strategy.66, 67 The 
activation of the HGF-Met pathway participates not only in the spreading and invasion of 
cancer stem cells but also in drug resistance to tyrosine kinase inhibitors (e.g., gefitinib and 
erlotinib) in patients with lung cancer.67-69 Taken together, it seems likely that HGF-Met 
inhibitors will provide further advances in the molecular targeting therapy of cancer. Several 
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inhibitors of the HGF-Met pathway are under preclinical and clinical development.60, 61 
 
Perspectives and conclusions 
 Current attention and progress in stem cell biology has facilitated an understanding of 
how stemness of stem cells is controlled by genetic programming, and how stem cells 
participate in tissue regeneration. A small population of hepatic progenitor cells, or stem cells 
with self-renewal and slow recycling characteristics, participate in long-term liver growth and 
the renewal of hepatocytes. However, liver regeneration mainly depends on the proliferation 
of mature hepatocytes. The key to understanding liver regeneration remains to find out how 
liver tissue architecture and homeostasis of liver mass are precisely regulated, before, during 
and after the regenerative response. 
 Growth factors and their receptor tyrosine kinases are divided into families based on 
structural and functional similarities. Among each family, a single growth factor activates 
multiple receptors with structural similarities, while a single growth factor receptor has 
multiple ligands with structural and functional similarities. By contrast, the sole receptor of 
HGF is Met, while the sole ligand of Met is HGF; the relationship between HGF and Met is a 
“one-to-one relationship.” Moreover, as demonstrated in systemic and conditional knockout 
mice with Met, HGF has unique physiological and therapeutic actions that are not substituted 
by other growth factors, at least not fully. Taken together, HGF and Met have remarkable 
potential value as targets in drug discovery and development, from aspects that are both 
agonistic / activating and antagonistic / inhibiting. The one-to-one relationship for HGF-Met 
should facilitate future drug discovery and design based on the crystal structures of HGF 
and/or Met for a small molecular activator or inhibitor of HGF-Met. Perhaps small molecular 
inducers or suppressors for HGF are also potential candidates in drug discovery.  
 It has been 20 years since we published our first HGF review article (“Hepatocyte 
growth factor: molecular structure and implications for a central role in liver regeneration”) in 
the Journal of Gastroenterology and Hepatology. The progress and diversity of research on 
HGF during the past 20 years have been remarkable. It is no longer possible to 
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comprehensively review this progress in a single article. Our intent was to describe the 
structural and functional characteristics and the therapeutic significance of HGF. Drug 
development using growth factors remains a challenge, but extensive studies to address the 
therapeutic effects of HGF have provided enough significance to develop agonists and 
antagonists of the HGF/Met system as biological drugs in regeneration-based or anti-cancer 
therapies. We propose that the further development of HGF as a therapeutic drug target is 
well worth the challenge.  
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Table 1. Landmark events in HGF research 
 
Year Events References (ref. No.)
1984 
 
Identification and partial characterization of HGF as mitogenic protein for hepatocytes  
 
Nakamura et al., 1984 (1) 





Purification of rat HGF from platelets 
 
Identification and partial characterization of scatter factor as fibroblast-derived cell motility factor 
 
Nakamura et al., 1987 (3) 
 




Purification of human HGF from plasma 
 





Purification of rabbit HGF from plasma 
 
cDNA cloning for human HGF 
 
 
Purification of mouse scatter factor from culture supernatant of fibroblasts 
 
Zarnegar & Michalopoulos, 1989 (5) 
 
Nakamura et al., 1989 (6) 
Miyazawa et al., 1989 (7) 
 
Gherardi et al., 1989 (70) 
1990 
 
Purification of human scatter factor from culture supernatant of fibroblasts Weidner et al., 1990 (54) 
1991 
 
Establishment of notion that scatter factor is identical molecule to HGF 
 
Identification of c-Met protooncogene product as receptor for HGF 
 
 
Identification of epithelial 3D-morphogen as HGF 
 




Bottaro et al., 1991 (12) 
Naldini et al., 1991 (13) 
 
Montesano et al., 1991 (11) 
 
Shima et al., 1991 (10) 
 
1992 In vivo therapeutic actions of HGF using recombinant HGF 
 
Ishiki et al., 1992 (71) 
1995 Generation of knockout mice disrupted with HGF or Met gene 
 
 
Schmidt et al., 1995 (14) 
Uehara et al., 1995 (15) 
Bladt et al., 1995 (16) 
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Therapeutic action of HGF for liver cirrhosis as fibrotic and chronic inflammatory disorder 
 
 
Matsuda et al., 1995 (72) 
1997 
 
Identification of germline mutations in Met gene in patients with hereditary and sporadic papillary renal cancer 
 
Isolation of NK4 as specific inhibitory molecule for HGF-Met pathway 
 
Schmidt et al., 1997 (57) 
 
Date et al., 1997 (12) 
 
1998 Determination of crystal structure of NK1 (N-terminal and the first kringle domains) 
 
In vivo therapeutic action of a specific inhibitor for HGF-Met in experimental cancer model 
 
Ultsch et al., 1998 (73) 
 
Date et al., 1998 (64) 
1999 Determination of crystal structure of NK1-dimer structure 
 
Chirgadze et al., 1999 (74) 
2002 Clinical study for treatment of patients with chronic leg ulcer with recombinant HGF protein 
 
Nayeri et al., 2002 (42) 
2003 Determination of crystal structure of Met tyrosine kinase domain 
 
Schiering et al., 2003 (52) 
2004 Determination of crystal structure of the HGF -chain in complex with the Sema-PSI domains of Met 
 
Clinical study for treatment of patients with critical limb ischemia by HGF gene drug 
 
Stamos et al., 2004 (51) 
 
Morishita et al., 2004 (43) 





Double-blind clinical trial for treatment of patients with critical limb ischemia by HGF gene drug 
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Table 2. Target cell types of HGF. 
 
 
Tissue type Target cell type 
    
Hepato-biliary and pancreas  hepatocyte 
 hepatoblast 
 bile duct epithelial cell 
 pancreatic  cell 
 
Gastrointestinal gastric epithelial cell 
 intestinal mucosal epithelial cell 
 
Kidney renal tubular cell 
 podocyte 
 
Lung bronchial epithelial cell 
 alveolar type II epithelial cell 
 
Nervous neuron (hippocampal neuron, cerebral cortex neuron, midbrain 
dopaminergic neuron, cerebellar granular neuron, motor neuron, 
thalamic neuron, sensory neuron, sympathetic neuron, 
parasympathetic neuron, subventiricular zone neural stem-like cell) 
 Schwann cell 
 astrocyte 
 oligodendrocyte progenitor cell 
 
Cardiovascular and lymphatic  cardiomyocyte (in hypoxic condition) 
 vascular endothelial cell 
 lymphatic vessel cell 
 
Hematopoietic and immune dendritic cell 
 hematopoietic stem/progenitor cell 
 monocyte-osteoclast 
 macrophage (conditionally) 
 
Skin and eye keratinocyte 
 melanocyte 
 hair bulb keratinocyte 
 corneal epithelial cell 
 
Muscle, bone, and joint muscle satellite cell 
 myogenic precursor cell 
 articular chondrocyte 
 
Glands mammary gland epithelial cell 
 submandibular gland epithelial cell 
 salivary gland epithelial cell 
 prostate epithelial cell 
 thyroid cell 
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Table 3. Therapeutic approaches with recombinant HGF in various disease models in various tissues. 
 
Tissues and disease models 
 
Model for injury or diseases 
 
Observed therapeutic effects References 
Liver    
Acute hepatitis -Naphthylisothiocyanate or 
CCl4 
Enhancement of hepatocyte proliferation 
Suppression of serum ALT 
Ishiki et al., Hepatology, 1992; 16: 
1227 
 -Naphthylisothiocyanate Decreases in serum ALT, AST, bilirubin 
Suppression of parenchymal lesions 




Suppression of serum ALT, AST 
 
Masunaga et al., Eur J Pharmacol, 
1998; 342: 267 
 Ischemia-reperfusion Suppression of mortality, serum ALT, and necrotic hepatocytes 
Inhibition of neutrophil infiltration  
Enhancement of hepatocyte growth 
Sakakura et al., J Surg Res, 2000; 92: 
261 
 Ischemia-reperfusion Suppression of necrotic hepatocytes, serum ALT, AST 
Suppression of oxidative stress 
Oe et al., J Hepatol, 2001; 34: 832 
 -Naphthylisothiocyanate + 
partial hepatectomy 
Enhancement hepatocyte proliferation 
Decrease in serum bilirubin 
Yoshikawa et al., J Surg Res, 1998; 
78: 54 
 Cholestasis Bile duct ligation 

Reduction in necrotic and apoptotic hepatocytes  
Decrease in serum AST, ALT 
Li et al., Am J Physiol, 2007; 292: 
G639 
 Fulminant hepatitis Agonistic anti-FAS antibody Suppression of hepatocyte apoptosis, serum ALT, and mortality Kosai et al., Biochem Biophys Res 
Commun, 1998; 244: 638 
 LPS + D-galactosamine Suppression of hepatocyte apoptosis, serum ALT, and mortality Kosai et al., Hepatol, 1999; 30: 151 
Liver cirrhosis Dimethylnitrosamine Improvement of survival and liver function 
Reduction in extracellular matrix accumulation 
Decrease in serum AST, ALT 
Matsuda et al., J Biochem, 1995; 118: 
643 
 CCl4, dimethylnitrosamine, or 
porcine serum 
Improvement of survival and liver function 
Reduction in extracellular matrix accumulation and serum AST level 
Matsuda et al., Hepatol, 1997; 26: 81 
 Thioacetamide 
 




Reduction in extracellular matrix accumulation and myofibroblasts 
Increase in apoptosis in myofibroblasts 
Kim et al., Am J Pathol, 2005; 166: 
1017 
 Dimethylnitrosamine Reduction in extracellular matrix accumulation 
Decrease in serum ALT and TGF- levels 
Increase in serum albumin and liver weight 
Kusumoto et al., Int J Mol Med, 2006; 
17: 503 
Liver cirrhosis + hepatic 
surgery 
Dimethylnitrosamine + portal 
branch ligation + partial 
hepatectomy 
Promotion of survival 
Decrease in serum AST, ALT, bilirubin 
Increase in liver weight 
Kaido et al., Hepatol, 1998; 28: 756 
Alcoholic steatohepatitis Ethanol-containing diet Decrease in hepatic lipids Tahara et al., J Clin Invest, 1999; 103: 
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Increase in serum lipids and lipoproteins 313 
    
Gastrointestinal    
Ulcerative colitis Dextran sulfate sodium Suppression of histological damage and loss of weight 
Enhancement of epithelial cell proliferation 
Tahara et al., J Pharmacol Exp 
Therapeutics, 2003; 307: 146 
 2,4,6-trinitrobenzene sulfonic acid Suppression of colonic ulcer coverage and large intestinal shortening 
Reduction in inflammatory cells and enhancement of epithelial cell growth 
Numata et al., Inflamm Bowel Dis, 
2005; 11: 551 
Gastric ulcer Cryoinjury 
 
Enhancement of epithelial cell proliferation Schmassmann et al., Gastroenterol, 
1997; 113: 1858 
Gastric injury Cisplatin  Nakahira et al., Biochem Biophys Res 
Commun, 2006; 341: 897 
    
Kidney    
Acute kidney injury HgCl2 or cisplatin Suppression of renal injury 
Enhancement of tubular proliferation 
Kawaida et al., Proc Natl Acad Sci 
USA, 1994; 91: 4357 
 Ischemia Enhancement of tubular proliferation Miller et a., Am J Physiol, 1994; 266: 
F129 
 Cyclosporin A Enhancement of tubular proliferation 
Suppression of tubular pathology (vacuolization) 
Amaike et al., Cytokine, 1996; 8: 387 
 HgCl2 Suppression of renal dysfunction 
Suppression of tubular apoptosis 
Yamasaki et al., Nephron, 2002; 90: 
195 
 Glycerol Suppression of tubular necrosis and improvement of renal function  
Prevention of mortality 
Nagano et al., Nephron, 2002; 91: 730 
 Tacrolims/FK506 Suppression of injury and decrease in serum creatinine 
Enhancement of renal cell proliferation 
Takada et al., Transpl Int, 1999; 12: 27 
Acute renal inflammation Tumor necrosis factor- Decrease in sequestration of circulating macrophages in the kidney 
Suppression of acute renal inflammation 
Gong et al., Kidney Int, 2006; 69: 
1166 
Septic acute renal failure Lipopolysaccharide Suppression of mortality 
Suppression in blood urea nitrogen and AST 
Kamimoto et al., Biochem Biophys 
Res Commun, 2009; 380: 333 
Diabetic nephropathy Streptozotocin Decrease in albuminurea 
Suppression of glomerular and tubulointerstitial fibrosis 
Improvement of renal function 
Mizuno & Nakamura, Am J Physiol, 
2004; 286: F134 
Chronic kidney disease Spontaneous due to tensin2 
mutation 
Improvement of glomerular and tubulointerstitial fibrosis 
Enhancement of tubular proliferation 
Improvement of renal function and decrease in albuminurea 
Mizuno et al., J Clin Invest, 1998; 
101: 1827 
 5/6 nephrectomy Suppression of renal inflammation 
Decrease in sequestration of circulating macrophages in the kidney 
Gong et al., J Am Soc Nephrol, 2006; 
17: 2464 
 Unilateral ureteral obstruction Improvement of tubulointerstitial fibrosis 
Increase in tubular proliferation and decrease in tubular apoptosis 
Mizuno et al., Kid Int, 2001; 59: 1304 
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 Unilateral ureteral obstruction Improvement of tubulointerstitial fibrosis Yang & Liu, Am J Physiol, 2003; 284: 
F349 




Ischemia and transplantation Prevention of tubular cell death after ischemia and transplantaion 
Suppression of proteinurea and fibrotic change of the kidney 
Prevention of mortality 
Azuma et al., J Am Soc Nephrol, 
2001; 12: 1280 
    
Cardiovascular    
Critical limb ischemia Hindimb ischemia Enhancement of collateral blood vessel formation 
Increase in blood vessel density and blood flow 
Van Belle et al., Circulation, 1998; 97: 
381 
 Hindimb ischemia Enhancement of collateral blood vessel formation 
 
Morishita et al., Hypertension, 1999; 
33: 1379 
 Hindimb ischemia Improvement in the recovery of blood flow by slow release delivery Marui et al., J Vasc Surg, 2005; 41: 82 
Neointimal hyperplasia Balloon injury Reduction in intimal area 
Enhancement of regeneration of endothelial cell layer 
Yasuda et al., Circulation, 2000; 101: 
2546 
Coronary artery disease Chronic ischemia Improvement in regional myocardial blood flow 
Improvement in myocardial function 
Yamaguchi et al., Surg Today, 2005; 
35: 855 
Myocardial infarction Ischemia-reperfusion Reduction in infract area, apoptosis in cardiomyocytes, and mortality 
Improvement of cardiac function 




Promotion of improvement in cardiac function 
Suppression of myocardial apoptosis and hypertrophy 
Jin et al., J Pharmacol Exp 
Therapeutics, 2003; 304: 654 
Cardiac allograft 
vasculopathy 
Ischemia and transplantation Promotion of survival of allografts 
Suppression of myocardial inflammation apoptosis  
Prevention of cardiac allograft vasculopathy and interstitial fibrosis 
Yamaura et al., Circulation, 2004; 110: 
1650 
Dilated cardiomyopathy Mutation in -sarcoglycan Improvement of cardiac fibrosis and echocardiographic function 
Suppression of myocardial apoptosis and hypertrophy 
Nakamura et al., Am J Physiol, 2005; 
288: H2131 
    
Respiratory    
Acute lung injury Intratracheal HCl infusion 
 
Enhancement of proliferation of airway and alveolar epithelial cells Ohmichi et al., Am J Physiol, 1996; 
270: L1031 
 Ischemia-reperfusion Suppression of histological damage  
Decrease in apoptosis 
Makiuchi et al., J Heart Lung 
Transplant, 2007; 26: 935 
Lung fibrosis Bleomycin 
 
Suppression and improvement of fibrosis Yaekashiwa et al., Am J Respir Crit 
Care Med, 1997; 156: 1937 
 Bleomycin Decrease in extracellular matrix deposition 
Enhancement in proliferation of epithelial cells 
Dohi et al., Am J Respir Crit Care 
Med, 2000; 162: 2302 
 Bleomycin Suppression and improvement of fibrosis Mizuno et al., FASEB J, 2005; 19: 580 
Pulmonary emphysema Elastase Regeneration of alveolar structure 
Promotion of recruitment of bone marrow-derived progenitor cells into 
Ishizawa et al., Biochem Biophys Res 
Commun, 2004; 324: 276 
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alveolar epithelial and endothelial cells 
Resection Left peumonectomy Enhancement of alveolar and airway epithelial cells Sakamaki et al., Am J Resp Cell Mol 
Biol, 2002; 26: 525 
Allergic airway 
inflammation / asthema 
Sensitization and challenge with 
ovalbumin 
Suppression of airway inflammation, collagen deposition, smooth muscle 
hyperplasia, and remodeling 
Reduction in Th2 cytokines and fibrogenic growth factors 
Ito et al., Am J Respir Cell Mol Biol, 
2005; 32: 268 
 Sensitization and challenge with 
ovalbumin 
Suppression of eosinophylic airway inflammation 
Suppression of antigen-induced allergic immune responses 
Okunishi et al., Int Arch Allergy 
Immunol, 2009; 149 Suppl. 1: 14 
Vocal fold scarring Removal of the lamina propria Better vibration interms of mucosal wave amplitude and glottal closure 
Reduction in collagen deposition and restoration of hyaluronic acid and 
elastin 
Ohno et al., Ann Otol Rhinol 
Laryngol, 2007; 116: 762 
 Removal of the lamina propria Better function (vibration) of larynge 
Reduction in collagen deposition 
Kishimoto et al., Laryngoscope, 2010; 
120: 108 
    
Skin    
Wound healing Full-thickness cutaneous excision 
in diabetic mice 
Promotion of wound closure, re-epithelialization, angiogenesis, granulation 
tissue formation 
Yoshida et al., Growth Factors, 2004; 
22: 111 
  Promotion of recruitment of neutrophils, monocytes, macrophages, 
endothelial cells, and re-epithelialization, granulation tissue formation and 
angiogenesis 
Bevan et al., J Pathol, 2004; 203: 831 
    
Nervous and sensory    
Cerebral ischemia Occlusion of carotid arteries Decrease in delayed neuronal death in the hippocanpus Miyazawa et al., J Cereb Blood Flow 
Metab, 1998; 18: 345 
 Transient occlusion of arteries Decrease in the infarct size 
Increase in blood vessel density 
Tsuzuki et al., Neurol Res, 2001; 23: 
417 
 Microsphere embolism Prevention of learning and memory dysfunction 
Suppression of endothelial cell apoptosis and necrotic tissue damage 
Date et al., J Neurosci Res, 2004; 78: 
442 
 Transient forebrain ischemia (the 
four-vessel occlusion) 
Suppression of neuronal cell death in hippocanpal neurons Niimura et al., Neurosci Lett, 2006; 
407: 136 
 Transient middle cerebral artery 
occlusion 
Decrease in the infarct size 
Suppression of apoptotic neurons and increase in autophagic response 
Shang et al., J Neurosci Res, 2010; 88: 
2197 




Mutation in superoxide dismutase Suppression of degeneration of motor neurons and disease progression 
Promotion of survival 
Ishigaki et al., J Neuropathol Exp 
Neurol, 2007; 66: 1037 
Hydrocephalus Transforming growth factor- Suppression of fibrosis Tada et al., Neurobiol Dis, 2006; 21: 
576-586 
Retinal injury Ischemia-reperfusion 
 
Decrease in apoptosis in ganglion cell layer and inner nuclear layer 
Increase in the inner retinal thickness and neuronal function 
Shibuki et al., Invest Ophthalmol Vis 
Sci, 2002; 43: 528 
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Photoreceotr degeneration / 
Retinitis pigmentosa 
Sodium iodate Better structural preservation of the outer retina 
Better functional preservation of retinal pigment epithelium and 
photoreceptor cells 
Ohtaka et al., Current Eye Res, 2006; 
31: 347 
 Phototoxicity (strong fluorescent 
light) 
Better the morphological and functional preservation of photoreceptor cells 
Suppression of apoptosis in photoreceptor cells 
Machida et al., Invest Ophthalmol Vis 
Sci, 2004; 45: 4174 
Difficulty in hearing Noise-induced hearing loss Protective in the auditory function 
Reduction in the loss of outer hair cell loss 
Inaoka et al., Acta Oto-Laryngologica, 
2009; 129: 453 
    
Muscloskeletal    
Articular cartilage injury Osteochondral defects Promotion of repair of osteochondral defects Wakitani et al., Acta Orthop Scand, 
1997; 68: 474-480 
Skeletal muscle injury Freeze damage Inhibition of muscle differentiation and retardation of muscle regeneration 
 
Miller et al., Am J Physiol, 2000; 278: 
C174 
Rheumatoid arthritis Type II Collagen-induced arthritis Enhancement of Th2-type immune response 
Inhibition of development of collagen-induced arthritis 
Okunishi et al., J Immunol, 2007, 179: 
5504 
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Figure legends 
 
Fig. 1. Structural characteristic of HGF (A) and Met (B). Sema, the domain found in 
semaphorin receptors; PSI, the domain found in plexins, semaphorins and integrins; IPT, the 
domain found in immunoglobulins, plexins and transcription factors. 
 
Fig. 2. Outline for biological and physiological actions of HGF, which participates in tissue 
protection and regeneration by HGF, and therapeutic actions of HGF. 
 
Fig. 3. Crystal structures for the complex of HGF -chain and the Met Sema domain (A) and 
the Met tyrosine kinase domain (B). The crystal structures for the complex of HGF -chain 
and the Met Sema domain were reported by Stamos et al. (2003) (PDB number: 1SHY). The 
crystal structure for Met tyrosine kinase was reported by Schiering et al. (2003) (PDB number 
1ROP). In B, the activation loop (A-loop) is shown in yellow, K-252a in green, and selected 
tyrosine residues (Y1234F, Y1235D, Y1349, Y1356) are in blue.  
 
Fig. 4. Outline for distinct approaches targeting HGF and Met for potential cancer treatment 
(A), outline for biological activity of NK4 as a competitive HGF-antagonist (B), and 
anti-cancer action of NK4 (C, D). Inhibitory effect of NK4 on tumor invasion (C) and cancer 
metastasis (D). Photographs in C show invasion of human malignant mesothelioma cells in a 
3-D collagen gel. Photographs in D show appearance of mesentery with disseminative 
metastasis of pancreatic cancer in mice. NK4 inhibited 3-D tumor invasion (C) and cancer 
metastasis (D).  
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HGF-antagonists (NK4, NK1) 
uncleavable HGF 
Neutralizing mAb against HGF 
decoy Met (Met extracellular) 
neutralizing peptide, siRNA
Inhbitory mAb against MET 
siRNA
Tyrosine kinase inhibitor 
(XL184, GSK1363089, ARQ197, 
AMG 208, JNJ38877605, 
MK-2461, PF-02341066, 
BMS-777607, PHA-665752, etc)
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